An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Prior treatment

• Have presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to
  • poorly controlled diabetes or hypertension
  • chronic kidney disease stage IIIa or IIIb, IV, or V
  • symptomatic heart failure according to New York Heart Association class II, III, or IV
  • myocardial infarction,unstable angina pectoris, stroke, or transient ischemic attack within the past 12 months before randomization
  • severe chronic pulmonary disease, for example, requiring oxygen therapy
  • major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to
  • systemic lupus erythematosus
  • psoriatic arthritis
  • axial spondyloarthritis,including ankylosing spondylitis and non-radiographic axial spondyloarthritis
  • reactive arthritis
  • gout
  • scleroderma
  • polymyositis
  • dermatomyositis
  • active fibromyalgia, or
  • multiple sclerosis

Other

• Have Class IV RA according to ACR revised criteria

• Have a diagnosis of adult-onset RA for at least 3 months prior to screening as defined by the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria.
• Have moderately-to-severely active RA at screening and baseline, defined by the presence of
  • ≥6 swollen joints based on 66 joint count, and
  • ≥6 tender joints based on 68 joint count.
• Have had a history of failure (an inadequate response, intolerance, or loss of response) to at least 1 conventional synthetic disease modifying anti rheumatic drug (csDMARD) and either 1 biologic (bDMARD), or targeted synthetic (tsDMARD) treatment.